Pulmonx Q1 revenue $10.8M (+17% YoY); net loss $15.8M; reaffirms FY 2022 guidance

Pulmonx Corp

2022-Q1 EPS reported -$0.43 revenue$10,785,000

Worldwide revenue $10.8M, up 17% YoY (20% constant currency); US revenue $6.0M (+40%).
Net loss $15.8M ($0.43/share) vs. $12.5M loss ($0.35/share) in Q1 2021.
Gross margin improved to 75% from 72% YoY, driven by production efficiencies.
Added 16 new US Zephyr Valve treatment centers; total 230 centers.
FY 2022 outlook unchanged: revenue $55-60M; operating expenses $100-105M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.